Ackman Sees Confidence Restored in Valeant Pharma (VRX) After 10-K Filed, New Leadership Identified
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Pershing Square cooperating with U.S. probe - Reuters
March 24, 2016 4:18 PM EDTPershing Square cooperating with U.S. probe - Reuters
... MoreValeant Pharma (VRX) Enters Information Sharing Agreement with Pershing Square
March 23, 2016 4:37 PM EDTPershing Square filed an amended 13D on Valeant Pharma (NYSE: VRX) today. The following letter was disclosed:
Dear Mr. Pearson:
I am delighted to join the Valeant Pharmaceuticals International, Inc. (Valeant) board, and I look forward to making a contribution to the company.
This letter, intended solely for the benefit of Valeant, contains a series of undertakings by myself, my firm and the investment funds that we advise (collectively, Pershing Square or we). The undertakings in the following two paragraphs of this letter will be effective so long as the confidential... More
